Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau

Pathological accumulation of four-repeat (4R) tau is central to several frontotemporal dementia (FTD) subtypes but human neuronal models amenable to high-throughput screening of 4R tau-targeting therapies remain limited. To address this, we developed iPSC-derived i ³ Neuron (i ³ N) lines expressing >75% 4R tau, driven by FTD splice-shifting mutations (S305N or S305N/IVS10+3). These neurons develop hyperphosphorylated tau and demonstrate somatodendritic mis-localisation. Unlike other stem cell models of tauopathy, these i ³ N neurons develop endogenous seed-competent tau and present pFTAA-positive tau assemblies after 28 days in culture. For scalable screening, we CRISPR-engineered a HiBiT luminescence tag at the endogenous MAPT locus into the S305N/IVS10+3 iPSC line, enabling precise quantification of tau levels and pharmacological responses. The model responded predictably to compounds affecting tau clearance, demonstrating its suitability for drug discovery. Overall, this i ³ N platform recapitulates key features of 4R tauopathy and provides a robust system to identify therapeutic modulators of pathological tau.